Samsung BioLogics Co Ltd

207940: XKRX (KOR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|!>!&nLOCK|k%&pLOCK|q?#>l>

Samsung Biologics Earnings: On Track to Meet Management's 2025 Guidance

Samsung Biologics' first-quarter revenue grew 37% to KRW 1.3 trillion, driven by higher contribution from the completion of Plant 4 in 2024, strong biosimilar sales, and favorable currency impact.

Sponsor Center